Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells

被引:55
作者
Dong, Zhao Ming
Aplin, Alfred C. [2 ]
Nicosia, Roberto F. [1 ,2 ]
机构
[1] VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S 113, Pathol & Lab Med Serv, Seattle, WA 98108 USA
[2] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
关键词
Macrophages; dendritic cells; myeloid cells; neovascularization; arteriogenesis; ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; HUMAN PERIPHERAL-BLOOD; HEMATOPOIETIC STEM; PROGENITOR CELLS; NECROSIS-FACTOR; MYELOID CELLS; MURINE MODEL; DNA VACCINE; TNF-ALPHA;
D O I
10.2174/138161209787315783
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis during reactive and pathologic processes is characteristically associated with inflammation. Macrophages and dendritic cells present in the inflammatory infiltrate contribute to the angiogenic process by multiple mechanisms. Macrophages produce a broad array of angiogenic growth factors and cytokines, generate conduits for blood flow through proteolytic mechanisms, and promote the remodeling of arterioles into arteries. They can also inhibit angiogenesis and cause reabsorption of neovessels by inducing endothelial cell death. Dendritic cells can stimulate or inhibit angiogenesis depending on their activation status and subset specificity. Dendritic cells stimulate angiogenesis by secreting angiogenic factors and cytokines, promoting the proangiogenic activity of T lymphocytes, and trans-differentiating into endothelial cells. Inflammatory infiltrates associated with angiogenesis also contain Tie2+, VEGFR2+, and GR1+ myelomonocytic cells which actively regulate the angiogenic process through paracrine mechanisms. In this paper we review our current knowledge of this field and discuss how recent advances have provided the rationale for novel therapeutic approaches against cancer.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 173 条
[81]   Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice [J].
Koga, Mitsuhisa ;
Kai, Hisashi ;
Egami, Kimiyasu ;
Murohara, Toyoaki ;
Ikeda, Ayami ;
Yasuoka, Suguru ;
Egashira, Kensuke ;
Matsuishi, Toyojiro ;
Kai, Mamiko ;
Kataoka, Yasufumi ;
Kuwano, Michihiko ;
Imaizumi, Tsutomu .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 365 (02) :279-284
[82]   Cooperative effect of TNF alpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity [J].
Koolwijk, P ;
vanErck, MGM ;
deVree, WJA ;
Vermeer, MA ;
Weich, HA ;
Hanemaaijer, R ;
vanHinsbergh, VWM .
JOURNAL OF CELL BIOLOGY, 1996, 132 (06) :1177-1188
[83]   Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor [J].
Kurihara, T ;
Warr, G ;
Loy, J ;
Bravo, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1757-1762
[84]   Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2 [J].
Kuziel, WA ;
Morgan, SJ ;
Dawson, TC ;
Griffin, S ;
Smithies, O ;
Ley, K ;
Maeda, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) :12053-12058
[85]   Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth [J].
Laakkonen, Pirjo ;
Waltari, Marika ;
Holopainen, Tanja ;
Takahashi, Takashi ;
Pytowski, Bronislaw ;
Steiner, Philipp ;
Hicklin, Daniel ;
Persaud, Kris ;
Tonra, James R. ;
Witte, Larry ;
Alitalo, Kari .
CANCER RESEARCH, 2007, 67 (02) :593-599
[86]  
LANG R, 1994, DEVELOPMENT, V120, P3395
[87]   MACROPHAGES ARE REQUIRED FOR CELL-DEATH AND TISSUE REMODELING IN THE DEVELOPING MOUSE EYE [J].
LANG, RA ;
BISHOP, JM .
CELL, 1993, 74 (03) :453-462
[88]   Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer [J].
Lee, Sung-Hyung ;
Mizutani, Noriko ;
Mizutani, Masato ;
Luo, Yunping ;
Zhou, He ;
Kaplan, Charles ;
Kim, Sung-Woo ;
Xiang, Rong ;
Reisfeld, Ralph A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (12) :1565-1574
[89]  
Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO
[90]  
2-6